Upgrade to SI Premium - Free Trial

Ionis Pharmaceuticals (IONS)

58.09 -0.04 (0.07%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/4/26)

Latest Headlines

Ionis Pharmaceuticals (IONS) PT Raised to $61 at BMO Capital September 4, 2026 7:41 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) September 4, 2026 6:44 AM - StreetInsider FDA approves Ionis Pharma's therapy to treat rare genetic disorder September 3, 2026 4:03 PM - StreetInsider FDA approves first treatment for Alexander disease September 3, 2026 3:52 PM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) August 31, 2026 6:50 AM - StreetInsider JPMorgan Reiterates Overweight Rating on Ionis Pharmaceuticals (IONS) August 31, 2026 2:41 AM - StreetInsider Alnylam stock drops on rival heart trial: Why analysts see core business safe August 28, 2026 8:25 AM - StreetInsider Canaccord Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) August 24, 2026 6:40 AM - StreetInsider Ionis to present olezarsen and ION775 data at ESC Congress 2026 August 20, 2026 7:00 AM - StreetInsider Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 August 20, 2026 7:00 AM - BizWire BMO Capital Starts Ionis Pharmaceuticals (IONS) at Market Perform August 18, 2026 4:13 PM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $76 at JPMorgan August 3, 2026 7:51 AM - StreetInsider Form 4 IONIS PHARMACEUTICALS For: Jul 30 Filed by: Hayden Michael R July 31, 2026 4:43 PM - SEC Filing Form S-8 IONIS PHARMACEUTICALS July 31, 2026 1:58 PM - SEC Filing Ionis Pharmaceuticals (IONS) PT Lowered to $95 at Wells Fargo July 30, 2026 8:35 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Lowered to $115 at H.C. Wainwright July 30, 2026 6:45 AM - StreetInsider Form 10-Q IONIS PHARMACEUTICALS For: Jun 30 July 29, 2026 5:06 PM - SEC Filing Form 8-K IONIS PHARMACEUTICALS For: Jul 29 July 29, 2026 7:31 AM - SEC Filing Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 37c July 29, 2026 7:20 AM - StreetInsider Ionis Pharmaceuticals chief scientific officer to retire in 2027 July 29, 2026 7:05 AM - StreetInsider Ionis announces Dr. Frank Bennett, chief scientific officer, to retire July 29, 2026 7:05 AM - BizWire Ionis reports second quarter 2026 financial results and highlights progress on key programs July 29, 2026 7:00 AM - BizWire H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) July 23, 2026 7:11 AM - StreetInsider Canaccord Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) July 23, 2026 7:09 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Lowered to $89 at Guggenheim July 21, 2026 6:45 AM - StreetInsider Raymond James sees potential for beats across biopharma coverage July 21, 2026 6:12 AM - StreetInsider Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: Reikes Peter N July 17, 2026 5:13 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: HANTSON LUDWIG July 17, 2026 5:13 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: HERMAN JOAN E July 17, 2026 5:13 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: BERTHELSEN SPENCER R July 17, 2026 5:12 PM - SEC Filing Wolfe Research Downgrades Ionis Pharmaceuticals (IONS) to Peerperform July 16, 2026 2:22 AM - StreetInsider Form 4 IONIS PHARMACEUTICALS For: Jul 07 Filed by: BENNETT C FRANK July 15, 2026 11:53 AM - SEC Filing Ionis to hold second quarter 2026 financial results webcast July 15, 2026 7:05 AM - BizWire Increasing unusual option volume: BCE EQPT MDY DOMO CC IONS ARKG FRMM TOI DINO July 15, 2026 4:24 AM - StreetInsider Biogen presents Phase 2 data on Alzheimer's drug diranersen at AAIC July 14, 2026 9:16 AM - StreetInsider Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease July 14, 2026 9:16 AM - BizWire H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) July 14, 2026 6:58 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright July 14, 2026 6:54 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Lowered to $85 at RBC Capital July 13, 2026 7:26 AM - StreetInsider Ionis starts Phase 1-2 trial of ION337 for Dravet syndrome July 13, 2026 7:01 AM - StreetInsider Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome July 13, 2026 7:00 AM - BizWire Ionis Pharmaceuticals (IONS) PT Lowered to $125 at H.C. Wainwright July 13, 2026 6:38 AM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright July 13, 2026 6:38 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Lowered to $110 at Morgan Stanley July 10, 2026 8:09 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Lowered to $95 at Canaccord July 10, 2026 6:49 AM - StreetInsider Ionis Pharmaceuticals (IONS) reaffirms guidance July 10, 2026 6:06 AM - StreetInsider Form 8-K IONIS PHARMACEUTICALS For: Jul 09 July 10, 2026 6:04 AM - SEC Filing Ionis Pharmaceuticals (IONS) PT Lowered to $90 at Barclays July 10, 2026 5:10 AM - StreetInsider Form 4 IONIS PHARMACEUTICALS For: Jul 07 Filed by: BENNETT C FRANK July 9, 2026 7:26 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 07 Filed by: Diaz Allene M. July 9, 2026 6:08 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 07 Filed by: Kordasiewicz Holly B. July 9, 2026 6:08 PM - SEC Filing Ionis Pharmaceuticals (IONS) PT Lowered to $100 at Citi July 9, 2026 4:01 PM - StreetInsider Form 8-K IONIS PHARMACEUTICALS For: Jul 09 July 9, 2026 2:55 PM - SEC Filing Ionis Pharmaceuticals (IONS) PT Lowered to $90 at Jefferies July 9, 2026 12:50 PM - StreetInsider Ionis Pharmaceuticals (IONS) PT Lowered to $86 at Needham July 9, 2026 12:40 PM - StreetInsider Ionis Pharmaceuticals (IONS) PT Lowered to $90 at BofA Securities July 9, 2026 11:54 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Lowered to $94 at TD Cowen July 9, 2026 11:53 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Lowered to $92 at Oppenheimer July 9, 2026 9:42 AM - StreetInsider Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile' July 9, 2026 6:16 AM - StreetInsider Ionis drug eplontersen misses primary endpoint in heart trial July 9, 2026 2:00 AM - StreetInsider Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy July 9, 2026 2:00 AM - BizWire Form 144 IONIS PHARMACEUTICALS Filed by: Diaz Allene M. July 7, 2026 4:33 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: Kordasiewicz Holly B. July 7, 2026 4:30 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: BENNETT C FRANK July 7, 2026 4:29 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: YANG MICHAEL J. July 6, 2026 6:51 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: LOSCALZO JOSEPH July 6, 2026 6:50 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: HERMAN JOAN E July 6, 2026 6:50 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: KLEIN JOSEPH III July 6, 2026 6:49 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: Hayden Michael R July 6, 2026 6:45 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: Diaz Allene M. July 6, 2026 6:45 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jul 01 Filed by: BERTHELSEN SPENCER R July 6, 2026 6:44 PM - SEC Filing Ionis completes enrollment in Phase 3 Angelman syndrome study July 6, 2026 7:00 AM - StreetInsider Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome July 6, 2026 7:00 AM - BizWire Form 144 IONIS PHARMACEUTICALS Filed by: KLEIN JOSEPH III July 1, 2026 5:29 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jun 26 Filed by: Baroldi Joseph June 30, 2026 5:49 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jun 26 Filed by: O'NEIL PATRICK R. June 30, 2026 5:48 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jun 26 Filed by: Schneider Eugene June 30, 2026 5:48 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jun 24 Filed by: Monia Brett P June 26, 2026 7:10 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jun 25 Filed by: Swayze Eric June 26, 2026 7:10 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: Baroldi Mariana June 26, 2026 5:49 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: O'NEIL PATRICK R. June 26, 2026 5:48 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: Schneider Eugene June 26, 2026 5:43 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: Swayze Eric June 25, 2026 6:54 PM - SEC Filing Needham Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) June 25, 2026 7:12 AM - StreetInsider Ionis Pharmaceuticals (IONS) PT Raised to $130 at H.C. Wainwright June 25, 2026 6:46 AM - StreetInsider Oppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS) June 25, 2026 3:33 AM - StreetInsider Ionis licenses zilganersen to Recordati for ex-U.S. markets June 25, 2026 2:59 AM - StreetInsider Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S. June 25, 2026 2:59 AM - BizWire Form 8-K IONIS PHARMACEUTICALS For: Jun 24 June 24, 2026 3:49 PM - SEC Filing FDA approves Ionis drug Tryngolza for severe hypertriglyceridemia June 24, 2026 2:39 PM - StreetInsider TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG) June 24, 2026 2:37 PM - BizWire Form 4 IONIS PHARMACEUTICALS For: Jun 12 Filed by: Kordasiewicz Holly B. June 16, 2026 5:26 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jun 15 Filed by: BERTHELSEN SPENCER R June 16, 2026 5:26 PM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: BERTHELSEN SPENCER R June 15, 2026 10:18 AM - SEC Filing Form 144 IONIS PHARMACEUTICALS Filed by: Kordasiewicz Holly B. June 12, 2026 4:29 PM - SEC Filing Form 8-K IONIS PHARMACEUTICALS For: Jun 12 June 12, 2026 2:20 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jun 04 Filed by: Reikes Peter N June 8, 2026 5:00 PM - SEC Filing Form 4 IONIS PHARMACEUTICALS For: Jun 04 Filed by: HANTSON LUDWIG June 8, 2026 4:59 PM - SEC Filing Form 3 IONIS PHARMACEUTICALS For: Jun 04 Filed by: Reikes Peter N June 8, 2026 4:59 PM - SEC Filing Form 3 IONIS PHARMACEUTICALS For: Jun 04 Filed by: HANTSON LUDWIG June 8, 2026 4:59 PM - SEC Filing Form 8-K IONIS PHARMACEUTICALS For: Jun 04 June 8, 2026 12:50 PM - SEC Filing Ionis appoints Ludwig Hantson to board of directors June 8, 2026 7:00 AM - StreetInsider Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors June 8, 2026 7:00 AM - BizWire Full Article List